Vancouver, British Columbia – June 21, 2011 – Sirona Biochem Corp. (TSX-V: SBM) (the “Company”), a biotechnology company specializing in carbohydrate chemistry technology, including the development of diabetes and obesity therapeutics, cosmeceuticals and biological ingredients, is pleased to announce it has launched a new website at www.sironabiochem.com.
With an aim to make it easier for readers to access information about Sirona Biochem, the new website includes an animation about our technology, enhanced content, improved navigation, downloading capabilities, access to social media feeds and a refreshed design.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company specializing in carbohydrate chemistry. We are applying a proprietary chemistry technique towards the development of diabetes therapeutics, cosmeceuticals and biological ingredients. Sirona Biochem aims to develop enhanced carbohydrate-based molecules by improving their pharmaceutical properties. Our lead product, a sodium glucose transporter (SGLT) inhibitor for Type 2 diabetes, recently achieved positive preclinical results. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.